Says one lobbyist, “The administration is imposing foreign pricecontrols from countries with socialized health care systems thatdeny their citizens access and discourage innovation.”
The lobbying groups for U.S. drugmakers aren'thappy about President Donald Trump's plan to borrow fromEurope's system of paying for some high-cost drugs.
On Thursday, Trump proposed cutting what Medicare pays for many costly drugs that areadministered in hospitals and clinics, using a new index of pricesthat would bring U.S. government payments closer to what Europeancountries pay.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
